Terbium-149 has been a theoretical gold standard for targeted alpha therapy since its discovery in 1950. Its unique ability to destroy cancer cells while simultaneously emitting a positron signal for real-time tumor imaging makes it a powerful clinical candidate. However, its 4.1-hour half-life and historical production constraints have prevented it from ever reaching human clinical trials. Current methods rely on specialized facilities that cannot meet the volume requirements for widespread medical use.

Marathon Fusion’s approach mirrors the successful model used for fluorine-18, where a stable, stockpilable precursor—in this case, gadolinium-150—is distributed to local sites. Medical facilities could then irradiate this precursor on-demand using existing cyclotron infrastructure. To create the necessary supply, the company proposes transmuting abundant europium-151. Their analysis suggests this could support tens of thousands of doses annually, with the potential to reach millions if scaled through emerging small fusion reactor technology.

While the theoretical framework is supported by established nuclear data, the process awaits direct experimental validation of its nuclear cross-section. Dr. Jason Parisi, principal research scientist at Marathon, emphasized that moving from models to experimental confirmation is the critical next step. If successful, the method could bridge the gap between long-standing clinical interest and actual patient care, turning a rare isotope into a staple of modern oncology.